Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenlin Shao

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature|September 18, 2009
Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingShih-Min A Huang, Yuji M Mishina, Shanming Liu, et al.
Nature Genetics|September 6, 2011
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusionAdam J Bass, Michael S Lawrence, Lear E Brace, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature|September 18, 2009
Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingShih-Min A Huang, Yuji M Mishina, Shanming Liu, et al.
Nature Genetics|September 6, 2011
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusionAdam J Bass, Michael S Lawrence, Lear E Brace, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 4